Meta Health (SGX:5DX) has signed a non-binding term sheet to acquire up to 30% of Aios Bio Sciences, a medical device company, according to a Wednesday filing on the Singapore Exchange.
The deal may also involve a larger stake. Payment could be made through the issuance of new shares in Meta Health, subject to due diligence and further negotiations.
The acquisition aims to diversify Meta Health's business into medical consumables and point-of-care diagnostics. The transaction is contingent on due diligence, board approval, and a 60-day exclusivity period.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。